1月28日，ImmunoMet Therapeutics公布其在研小分子Lixumistat联合吉西他滨（Gemcitabine）和白蛋白结合型紫杉醇（Nab-paclitaxel），作为一线疗法治疗晚期胰腺癌患者的结果。 胰腺癌因发病隐匿，恶性程度极高，预后效果极差，被称为“癌症之王”。近年来，针对胰腺癌的创新疗法不断增多，为胰腺癌治疗提供了新的选择。 近期，在研小分子Lixumistat联合吉 ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

To the best of our knowledge, this is the first study to provide information about feasibility and tolerability of the combination cisplatin/gemcitabine ... courses of chemotherapy, with a high ...

Phase I/Ib study of afatinib with capecitabine in patients with refractory solid tumors and pancreaticobiliary cancers. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

or chemotherapy (gemcitabine plus oxaliplatin). This is the first published clinical trial combining those two approaches; it yielded complete remission rates markedly higher than either approach ...

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

Perioperative durvalumab improved upon neoadjuvant chemotherapy in patients with cisplatin-eligible MIBC in the NIAGARA trial.

Sequential intravesical gemcitabine and docetaxel is associated with better oncologic outcomes compared with additional BCG in patients with BCG-unresponsive NMIBC and warrants a trial.

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...